Lina Zhou
Peking Union Medical College
16 Papers
1 Citations
Lina Zhou is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 4, co-authored 12 publications.
Chat about Author
Papers
Genomic heterogeneity of multiple synchronous lung cancer
Yu Liu,Jianjun Zhang,Lin Li,Guangliang Yin,Jianhua Zhang,Shan Zheng,Hannah Cheung,Ning Wu,Ning Lu,Xizeng Mao,L. Yang,Jiexin Zhang,Li Zhang,Sahil Seth,Huang Chen,Xingzhi Song,Kan Liu,Yong-qiang Xie,Lina Zhou,Chuanduo Zhao,Naijun Han,W Q Chen,Susu Zhang,Chen Longyun,Wenjun Cai,Miaozhong Shen,Ningzhi Xu,Shujun Cheng,Huanming Yang,J. Jack Lee,Arlene M. Correa,Junya Fujimoto,Carmen Behrens,Chi Wan Chow,William N. William,John V. Heymach,Waun Ki Hong,Stephen G. Swisher,Ignacio I. Wistuba,Jun Wang,Jun Wang,Dongmei Lin,Xiangyang Liu,P. Andrew Futreal,Yanning Gao +44 more
TL;DR: Analysis of genomic profiles of 15 lung adenocarcinomas and one regional lymph node metastasis from 6 patients with MSLC suggests different lung cancers in the same individual may have distinct genomic profiles and can be driven by distinct molecular events.
Long-term follow-up of persistent pulmonary pure ground-glass nodules with deep learning–assisted nodule segmentation
Linlin Qi,Botong Wu,Wei Tang,Lina Zhou,Yao Huang,Shijun Zhao,Li Liu,Meng Li,Li Zhang,Shi-Chao Feng,Donghui Hou,Zhen Zhou,Xiuli Li,Yizhou Wang,Ning Wu,Jianwei Wang +15 more
TL;DR: In this article, the authors investigated the natural history of persistent pulmonary pure ground-glass nodules (pGGNs) with deep learning-assisted nodule segmentation, and they used a convolutional neural network (CNN) to segment pGGNs.
68
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer
Shijun Zhao,Donghui Hou,Xiaomin Zheng,Wei Song,Xiaoqing Liu,Sicong Wang,Lina Zhou,Xiuli Tao,Lv Lv,Qi Sun,Yu-Jing Jin,Lieming Ding,Li Mao,Ning Wu +13 more
TL;DR: A magnetic resonance imaging (MRI) radiomic signature that can stratify survival and intracranial progression in ALK-positive NSCLC patients with brain metastases undergoing ensartinib treatment is developed, allowing follow-up and treatment to be tailored to the patient's individual risk profile.
Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer.
Donghui Hou,Weihua Li,Sicong Wang,Yao Huang,Jianwei Wang,Wei Tang,Lina Zhou,Linlin Qi,Ning Wu,Shijun Zhao +9 more
TL;DR: In this article, the authors compared the clinicopathologic and computed tomography (CT) imaging characteristics between primary and acquired EGFR T790M mutations in patients with NSCLC before treatment.
Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Donghui Hou,Xiaomin Zheng,Wei Song,Xiaoqing Liu,Sicong Wang,Lina Zhou,Xiuli Tao,Lv Lv,Qi Sun,Yu-Jing Jin,Zewei Zhang,Lieming Ding,Ning Wu,Shijun Zhao +13 more
TL;DR: In this paper, the potential value of computed tomography (CT) radiomic features in predicting progression-free survival (PFS) was explored in a multicenter phase 2 trial, and the impact of ALK variants and secondary ALK alterations on the clinical outcome (response duration) of patients receiving ensartinib.
11